Saba Abdulghani
Lisbon, Portugal
Sat 18
Awards 1 - 2013 ECTS / AMGEN BONE BIOLOGY FELLOWSHIP, 2013 ECTS / THE ALLIANCE FOR BETTER BONE HEALTH (WARNER CHILCOTT AND SANOFI) IAIN T BOYLE AWARD, 2013 ECTS PHILIPPE BORDIER CLINICAL AWARD, 2013 ECTS MIKE HORTON BASIC/TRANSLATIONAL AWARD
2010 ECTS / SERVIER FELLOWSHIP,
Lisbon, Portugal
Bo Abrahamsen
Mon 20 15:00
OP11
Oral Posters 2: Clinical
Health economic consequences of fractures in patients with osteoporosis: A national register based study of total and incremental health costs following fracture.
Yasmine Alanay
Istanbul, Turkey
Mon 20 08:00
S3.1
Symposium 3: Extreme bone phenotypes
Diagnosis and clinical management of of genetic skeletal disorders
Istanbul, Turkey
Omar Albagha
Edinburgh, UK
Tue 21 13:00
MTP14.1
Meet the Professor Sessions
ERC Grants - Room 5B
Edinburgh, UK
Tim Arnett
London, UK & Isabelle Orriss
Sun 19 12:45
MTP5
Meet the Professor Parallel Sessions
Mineralisation: the key role of extracellular ATP - Room 5C
London, UK & Isabelle Orriss
Terry Aspray
Newcastle upon Tyne, UK
Mon 20 15:05
OP12
Oral Posters 2: Clinical
Fracture Risk Assessment In A Primary Care Population: Case Finding Using Routine GP Data and a health reporting, analysis & intelligence delivery tool, In The United Kingdom
Newcastle upon Tyne, UK
Eman Azzam
Aberdeen, UK
Sun 19
Awards 2
2010 ECTS PHD STUDENTSHIP
Aberdeen, UK
Sun 19 15:35
OP28
Oral Posters 1: Pre-clinical
Functional assessment of Paget's disease-causing mutations in Sequestosome-1 (SQSTM1)
Aberdeen, UK
Susana Balcells
Barcelona, Spain
Mon 20 09:10
PP277
Plenary Orals 3
A genomic and transcriptomic approach to the high bone mass phenotype: evidence of heterogeneity and of additive effects of TWIST1, IL6R, DLX3 and PPARG
Barcelona, Spain
Ulrich Bang
Hvidovre, Denmark
Sun 19 15:10
OP3
Oral Posters 1: Clinical
The risk of fractures in cirrhosis and chronic pancreatitis. A Danish nationwide retrospective matched cohort study
Hvidovre, Denmark
Roland Baron
Boston, USA
Sat 18 17:30
OPC1
Opening Ceremony: ECTS 50th Anniversary Symposium: 50 years of research in bone and mineral metabolism
50 years of progress in bone biology
Boston, USA
Sun 19 18:55
Satellite Symposium - Current and Future Strategies for the Management of Osteoporosis: Signaling a Change in the Conversation - Supported by MSD
The Impact of Selective Cathepsin K Inhibition on Bone Homeostatis
Boston, USA
Sun 19 20:00
ECTS New Investigator Seminar and Social Gathering
Plenary Session: Bone Research – The Next 50 Years
Boston, USA
Claude Benhamou
North Wales, USA
Mon 20 15:45
OP20
Oral Posters 2: Clinical
Resolution of Effects on Bone Turnover Markers and Bone Mineral Density after Discontinuation of Long-term Bisphosphonate Use 
North Wales, USA
Charles Benson
indianapolis, USA
Tue 21 09:20
OC5.3
Orals 5 - Treatment of osteoporosis
Effect of blosozumab on bone mineral density: Results of a Phase 2 study of postmenopausal women with low bone mineraly density
indianapolis, USA
Åshild Bjørnerem
Tromsø, Norway
Mon 20 09:30
OC3.4
Plenary Orals 3
Cortical exceeds trabecular bone loss before menopause but net bone loss is modest because periosteal apposition occurs
Tromsø, Norway
Claudine Blin-Wakkach
Nice, France
Mon 20 11:30
W4.2
Workshop 4: Osteoclast activity and haematopoiesis
Are osteoclasts dispensable for haematopoietic stem cell maintenance and mobilization?
Nice, France
Nicolas Bonnet
Geneva, Switzerland
Sun 19 09:30
OC2.4
Plenary Orals 2
PPAR beta deficiency induces muscle and bone loss with aging but does not impair the bone biomechanical response to loading: a sarco-osteopenic mouse model
Geneva, Switzerland
Mon 20 09:50
OC4.6
Plenary Orals 4
Periostin (Postn) synergizes with osteocytes beta-catenin to mediate the adaptive skeletal response to loading
Geneva, Switzerland
Steve Boonen
Leuven, Belgium
Sat 18 11:00
CU1.4
Clinical Update 1
Medical management of Osteoporosis in men
Leuven, Belgium
Steven Boonen
Leuven, Belgium
Mon 20 18:35
Satellite Symposium - New evidence for osteoporosis therapy - Supported by Amgen in collaboration with GSK
Denosumab : valuable for my patients at increased risk for hip fracture?
Leuven, Belgium
Alan Boyde
London, UK
Sun 19 12:45
MTP1
Meet the Professor Parallel Sessions
ECTS Excellence in Research Lecture: Methods for assessing bone microstructure - AUDITORIUM III
London, UK
Robert Brommage
Texas, USA
Mon 20 09:00
OC4.1
Plenary Orals 4
High-Throughput DEXA and MicroCT Screening in Gene Knockout Mice Identifies Bone Mass Phenotypes
Texas, USA
Irene Bultink
Amsterdam, The Netherlands
Sat 18 13:30
CU2.3
Clinical Update 2
Osteoporosis in SLE
Amsterdam, The Netherlands
Liisa Byberg
Uppsala, Sweden
Sun 19 09:20
OC1.3
Plenary Orals 1
Size at birth is not associated with risk of hip fracture. Results from two population-based cohorts
Uppsala, Sweden
Joana Camilo
Lisbon, Portugal
Tue 21 13:00
MTP14.2
Meet the Professor Sessions
EU-Funding - Room 5B
Lisbon, Portugal
John Campbell
Mon 20
ECTS / ASBMR Clinical Debate: This house believes that muscle, not bone, is the preferred target to reduce non-vertebral fractures
In Support of the Motion
Leonar Cancela
Faro, Portugal
Sun 19 11:00
W2.1
Workshop 2: Developmental biology and bone
Fish as a model organism for mineralization related pathologies
Faro, Portugal
Leonor Cancela
Faro, Portugal
Sun 19 12:45
MTP4
Meet the Professor Parallel Sessions
Fish as a model system for exploring skeletal development and regeneration - Room 5B
Faro, Portugal
Helena Canhão
Lisbon, Portugal
Sat 18 17:20
Opening Ceremony
Welcome to Lisbon from the Chair of the Local Organising Committee
Lisbon, Portugal
Vincent Carpentier
Paris, France
Sun 19 15:45
OP10
Oral Posters 1: Clinical
Regional heterogeneity of trabecular bone microdamage density in association with trabecular microarchitecture and bone resorption in whole human lumbar vertebrae
Paris, France
Roland Chapurlat
Mon 20 15:35
OP18
Oral Posters 2: Clinical
Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate- A Randomized Placebo-Controlled trial
Emma Clark
(Bristol, UK)
Mon 20 11:30
W3.2
Workshop 3: Vertebral fractures
How are vertebral fractures best detected and diagnosed?
(Bristol, UK)
Cyrus Cooper
Southampton, UK
Sat 18 11:30
CU1.5
Clinical Update 1
Glucocorticoid-induced osteoporosis
Southampton, UK
Sat 18 15:35
Satellite Symposium - Treatment of Severe Osteoporosis: an update - supported by Lilly
Epidemiology of Fragility Fractures: an update
Southampton, UK
Addolorata Corrado
Foggia, Italy
Sun 19 15:15
OP4
Oral Posters 1: Clinical
Relationship between bone mineral density, body composition, skin sclerosis and serum 25(OH) vitamin D levels in  systemic sclerosis
Foggia, Italy
Peter Croucher
Sydney, Australia
Tue 21 11:15
W6.1
Workshop 6: Cancer cells and Bone
How do cancer cells home to bone?
Sydney, Australia
Steven Cummings
Mon 20
ECTS / ASBMR Clinical Debate: This house believes that muscle, not bone, is the preferred target to reduce non-vertebral fractures
Against the Motion
Tue 21 09:10
OC5.2
Orals 5 - Treatment of osteoporosis
Fracture Risk Factors During Treatment With Denosumab
Kevin Deere
Bristol, UK
Mon 20 09:20
OC3.3
Plenary Orals 3
Distinct relationships of intramuscular and subcutaneous fat with cortical bone: findings from a cross-sectional study of young adult males and females
Bristol, UK
Frederic Deschaseaux
Toulouse, France
Mon 20 15:10
OP33
Oral Posters 2: Pre-clinical
Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue
Toulouse, France
Adolfo Díez-Pérez
Barcelona, Spain
Sat 18 12:55
AHP1.2
Allied Health Professionals (AHP) Session
Compliance with Osteoporosis: Can we improve patient understanding through education?
Barcelona, Spain
Richard Eastell
Sat 18 13:45
AHP1.3
Allied Health Professionals (AHP) Session continued
Could compliance be improved through monitoring?
Marco Eijken
Rotterdam, Netherlands
Tue 21 12:15
W5.3
Workshop 5: Anabolic bone therapies
Therapeutic targeting of activin signaling
Rotterdam, Netherlands
John Eisman
Sydney, Australia
Tue 21 14:30
S5.2
Symposium 5: Uncoupling of resorption and formation
Effects of cathepsin K inhibition
Sydney, Australia
Erik Eriksen
Sat 18 09:30
CU1.1
Clinical Update 1
Osteoporosis in premenopausal women
Tue 21 13:00
MTP11
Meet the Professor Sessions
Long-term treatment of osteoporosis - Auditorium III
Astrid Fahrleitner-Pammer
Graz, Austria
Tue 21 09:50
OC5.6
Orals 5 - Treatment of osteoporosis
Testosterone Replacement has a Substantial Benefit on Bone Mass, Fracture Incidence, Libido and Sexual Activities in Male Cardiac Transplant Patients: A 5 Year Randomized Prospective Controlled Trial
Graz, Austria
Tue 21 11:15
W5.1
Workshop 5: Anabolic bone therapies
The effect of PTH on fracture healing
Graz, Austria
Andrea Fattore
Rome, Italy
Mon 20 15:45
OP40
Oral Posters 2: Pre-clinical
Insertion of the clcn7 gene mutation pG213R in mouse induces Autosomal Dominant Osteopetrosis Type II (ADO2).
Rome, Italy
Serge Ferrari
Mon 20 19:00
Satellite Symposium - New evidence for osteoporosis therapy - Supported by Amgen in collaboration with GSK
What is the relevance for BMD increase in fracture risk reduction?
Joao Fonseca
Lisboa, Portugal
Tue 21 13:00
MTP13
Meet the Professor Sessions
Arthritis, inflammation and bone: from bench to bedside - Room 5A
Lisboa, Portugal
Seiji Fukumoto
Tokushima, Japan
Mon 20 17:05
ES2.2
Educational Symposium 2
Low phosphate
Tokushima, Japan
Thomas Funck-Brentano
Paris, France
Sun 19 15:25
OP26
Oral Posters 1: Pre-clinical
Bone is the main target of activation of Canonical Wnt pathway in osteoarthritis
Paris, France
Harry Genant
San Francisco, USA
Sat 18 18:00
OPC2
Opening Ceremony: ECTS 50th Anniversary Symposium: 50 years of research in bone and mineral metabolism
50 years of progress in bone imaging
San Francisco, USA
Sun 19 20:00
ECTS New Investigator Seminar and Social Gathering
Plenary Session: Bone Research – The Next 50 Years
San Francisco, USA
Maude Gerbaix
Geneva, Switzerland
Mon 20 15:20
OP35
Oral Posters 2: Pre-clinical
Effects of a mutated sclerostin peptide on bone and lean mass in mice.
Geneva, Switzerland
C-C Glüer
Thousand Oaks, USA
Tue 21 09:30
OC5.4
Orals 5 - Treatment of osteoporosis
Effects of Romosozumab Administration on Trabecular and Cortical Bone Assessed With Quantitative Computed Tomography and Finite Element Analysis
Thousand Oaks, USA
Bérengère Gobin
NANTES cedex, France
Sun 19 21:15
PP139
ECTS New Investigator Seminar and Social Gathering
New PI3Kalpha-specific inhibitor, BYL719: therapeutic interest in osteosarcoma
NANTES cedex, France
Keith Godfrey
Southampton, UK
Sun 19 08:00
S1.1
Symposium 1: Developmental origins of metabolic bone disease
Developmental epigenetics and the intrauterine origins of chronic disease
Southampton, UK
Sun 19 12:45
MTP3
Meet the Professor Parallel Sessions
Epigenetic regulation: what and why? - Room 5A
Southampton, UK
Stephanie Gohin
London, UK
Tue 21 09:30
OC6.4
Orals 6 - Mineralisation and energy metabolism
Inhibition of PTH-induced vasorelaxation modulates its anabolic action
London, UK
Celia Gregson
Bristol, UK
Sun 19 09:00
OC1.1
Plenary Orals 1
Disease-specific perception of fracture risk and incident fracture rates among postmenopausal women: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)
Bristol, UK
Sun 19 21:05
PP31
ECTS New Investigator Seminar and Social Gathering
A GWAS in an extreme high bone mass population shows exess signal from genes associated with BMD in normal population
Bristol, UK
Nuria Guanabens
Sun 19 12:00
W1.3
Workshop 1: Fat and bone
Obesity,bariatric surgery and bone
Mon 20 12:45
MTP7
Meet the Professor Sessions
Clinical utility of bone turnover markers - Auditorium IV
Peyman Hadju
Marburg, Germany
Tue 21 12:15
W6.3
Workshop 6: Cancer cells and Bone
Clinical decision making in metastatic bone disease
Marburg, Germany
Tue 21 13:00
MTP12
Meet the Professor Sessions
Breast cancer treatment induced osteoporosis - pathophysiology, prevention and treatment - Auditorium IV
Marburg, Germany
Christine Hamann
Dresden, Germany
Sun 19 09:10
OC2.2
Plenary Orals 2
Intermittent human parathyroid hormone (1-84) treatment improves bone mass and bone defect healing in rats with type 2 diabetes mellitus
Dresden, Germany
Bolette Hartmann
Copenhagen, Denmark
Sat 18 14:50
PP111
Allied Health Professionals (AHP) Session continued
Abstract Presentation - The effect of gastric bypass treatment for obesity on hormones related to bone re-modeling and intestinal growth
Copenhagen, Denmark
Gary Hattersley
MA, USA
Sat 18 14:30
PP450
Allied Health Professionals (AHP) Session continued
Abstract Presentation - Transdermal Delivery of BA058, A Novel Analog of hPTHrP (1-34), with a Short Wear Time Patch in Preclinical and Clinical Studies
MA, USA
Tue 21 09:40
OC5.5
Orals 5 - Treatment of osteoporosis
Bone Anabolic Efficacy and Safety of BA058, A Novel Analog of hPTHrP: 12 Month Extension Data from a Phase 2 Clinical Trial in Postmenopausal Women with Osteoporosis
MA, USA
Glen Haugeberg
Oslo, Norway
Sat 18 13:00
CU2.2
Clinical Update 2
Osteoporosis and fragility fractures in rheumatoid arthritis
Oslo, Norway
Glenn Haugeberg
Bærum, Norway
Sun 19 15:20
PP22
Oral Posters 1: Clinical
Generalized Long Term Bone Loss in Early Rheumatoid Arthritis in the Biologic Treatment Era - A 10 Year prospective Observational Study
Bærum, Norway
Barbara Hauser
Edinburgh, UK
Sun 19 21:35
PP383
ECTS New Investigator Seminar and Social Gathering
Detection of autoantibodies to osteoprotegerin in patients with rheumatoid arthritis and their association with disease activity
Edinburgh, UK
Eric Haÿ
Paris, France
Mon 20 15:25
OP36
Oral Posters 2: Pre-clinical
N-Cadherin Governs Age-Related Determination in Mice Through Modulation of Wnt5a and Wnt10b.
Paris, France
Anne Heegard
Copenhagen, Denmark
Mon 20 12:45
MTP6
Meet the Professor Sessions
Bone Pain - Auditorium III
Copenhagen, Denmark
Eric Hesse
Huddinge, Sweden
Mon 20
NIW2
New Investigator Workshop 2
How to manage your research time and team
Huddinge, Sweden
Nicole Horwood
London, UK
Mon 20 11:00
W4.1
Workshop 4: Osteoclast activity and haematopoiesis
The relationship between osteoclasts and haematopoiesis
London, UK
Carmen Huesa
Paisley, UK
Tue 21 09:10
OC6.2
Orals 6 - Mineralisation and energy metabolism
Deficiency of the bone mineralisation inhibitor NPP1 protects against obesity and diabetes
Paisley, UK
Franz Jakob
Sat 18 15:30
Satellite Symposium - Treatment of Severe Osteoporosis: an update - supported by Lilly
Welcome & Introductions
Sat 18 16:50
Satellite Symposium - Treatment of Severe Osteoporosis: an update - supported by Lilly
Q & A and Closing Remarks
Professsor Kassim Javaid
Oxford, UK
Sun 19 08:30
S1.2
Symposium 1: Developmental origins of metabolic bone disease
Maternal environment and intrauterine skeletal development
Oxford, UK
Mari Kaartinen
Montreal, Canada
Mon 20 09:20
OC4.3
Plenary Orals 4
Severe osteopenia, increased bone marrow adipogenesis and fibronectin matrix changes in mice lacking both TG2 and FXIIIA transglutaminases
Montreal, Canada
Ivo Kalajzic
Farmington, USA
Sun 19 15:15
OP24
Oral Posters 1: Pre-clinical
Identification and Characterization of a Mesenchymal Progenitor Cell Population Involved in Fracture Healing
Farmington, USA
Gerard Karsenty
Tue 21 08:00
S4.1
Symposium 4: Energy metabolism and bone
Energy metabolism, bone and reproduction
Hua Ke
Thousand Oaks, USA
Mon 20 15:40
OP19
Oral Posters 2: Clinical
Effects of Sclerostin Antibody and Maintenance of New Bone Induced by Sclerostin Antibody in Animal Models
Thousand Oaks, USA
John Kemp
(Bristol, UK)
Sun 19 21:30
PP282
ECTS New Investigator Seminar and Social Gathering
Phenotypic dissection of bone mineral density facilitates the identification of skeletal site specificity on the genetic regulation of bone
(Bristol, UK)
Douglas Kiel
Boston, USA
Sun 19 14:15
S2.2
Symposium 2: Sarcopenia – causes and consequences
Sarcopenia: Prevalence and consequences
Boston, USA
Tue 21 09:00
OC5.1
Orals 5 - Treatment of osteoporosis
A Three Year Randomized Sham-Controlled Trial of Low Magnitude Mechanical Stimulation in an Elderly Sample:  The "VIBES" Trial
Boston, USA
Riku Kiviranta
Sun 19
Awards 2
2010 ECTS CAREER ESTABLISHMENT AWARD
Sun 19 15:30
OP7
Oral Posters 1: Clinical
Bone Marrow Fat Is Metabolically Distinct Fat Depot
Venkatesh Krishnan
Boston, USA
Sun 19 12:45
MTP2
Meet the Professor Parallel Sessions
The wnt signalling in and out of bone - AUDITORIUM IV
Boston, USA
Tue 21 11:45
W5.2
Workshop 5: Anabolic bone therapies
Wnt signaling - a clinical drug target
Boston, USA
Gisela Kuhn
Zurich, Switzerland
Mon 20 09:40
OC4.5
Plenary Orals 4
Mechanical loading increases the effect of sclerostin antibody treatment in a mouse model of high turnover osteoporosis
Zurich, Switzerland
Francois Lamoureux
Nantes, France
Sun 19 15:45
OP30
Oral Posters 1: Pre-clinical
Clusterin Inhibition using OGX-011 Synergistically Enhances Zoledronic Acid Activity in Osteosarcoma.
Nantes, France
Professor Bente Langdahl
Aarhus, Denmark
Sat 18 17:15
Opening Ceremony
Welcome to the congress from the ECTS President
Aarhus, Denmark
Willem Lems
Amsterdam, The Netherlands
Sat 18 14:30
CU2.5
Clinical Update 2
The effect of anti-inflammatory treatments (except GC) on bone
Amsterdam, The Netherlands
Sat 18 14:20
PP439
Allied Health Professionals (AHP) Session continued
Abstract presentation - The Direct And Indirect Costs Of An Osteoporotic Fracture: A Prospective Evaluation Of Elderly Patients With A Clinical Fracture
Amsterdam, The Netherlands
Su-Vern Lim
London, UK
Sun 19 09:50
OC2.6
Plenary Orals 2
Growth hormone excess in bGH transgenic mice adversely affects bone density, architecture and quality
London, UK
David Little
Sun 19 15:10
OP23
Oral Posters 1: Pre-clinical
MEK inhibitors in fracture healing and NF1 pseudarthrosis
Nerea Lopez
Edinburgh, UK
Mon 20 09:40
OC3.5
Plenary Orals 3
Genome-wide association identifies a new susceptibility locus at 4q35 associated with clinical vertebral fractures in post-menopausal women: The GEFOS-GENOMOS consortium.
Edinburgh, UK
John Loughlin
Newcastle, UK
Sun 19 17:05
ES1.2
Educational Symposium 1
Disease mechanisms
Newcastle, UK
Guillaume Mabilleau
Angers, France
Sun 19 09:40
OC2.5
Plenary Orals 2
Glucagon-like peptide 1 receptor is required for optimal bone strength and quality
Angers, France
Eleanor Mackie
Parkville, Australia
Mon 20 15:00
OP31
Oral Posters 2: Pre-clinical
ADIPOGENESIS OCCURS AT THE EXPENSE OF OSTEOBLAST DIFFERENTIATION IN PRIMARY OSTEOBLASTS DEFICIENT IN PROTEASE-ACTIVATED RECEPTOR-2
Parkville, Australia
Andrea Marques
Coimbra, Portugal
Sat 18 12:30
Allied Health Professionals (AHP) Session
Introduction to the highlights of the meeting
Coimbra, Portugal
Mary Matthews
Adelaide, Australia
Sun 19 15:05
OP22
Oral Posters 1: Pre-clinical
The Effect of mTORC1 on Postnatal Skeletal Development
Adelaide, Australia
Marta Maycas
Madrid, Spain
Mon 20 15:15
OP34
Oral Posters 2: Pre-clinical
Activation of the Parathyroid Hormone-Receptor is Involved in the Pro-survival Effect of Hypotonic Shock in Osteocyte-like MLO-Y4 Cells
Madrid, Spain
Ann McArdle
Liverpool, UK
Sun 19 13:45
S2.1
Symposium 2: Sarcopenia – causes and consequences
Skeletal muscle loss: sarcopenia and inactivity
Liverpool, UK
Eugene McCloskey
Sun 19 15:00
PP384
Oral Posters 1: Clinical
Does Vitamin D status impact on hip fracture incidence? - evidence of fracture variation with latitude and season in Sweden
Jose Melo-Gomes
Sun 19
Satellite Symposium - Current and Future Strategies for the Management of Osteoporosis: Signaling a Change in the Conversation - Supported by MSD
Welcome & Introductions
Sun 19 19:35
Satellite Symposium - Current and Future Strategies for the Management of Osteoporosis: Signaling a Change in the Conversation - Supported by MSD
Q & A and Closing Remarks
Daniela Merlotti
Siena, Italy
Sun 19 15:40
OP9
Oral Posters 1: Clinical
Interaction between FGF23 R176W mutation and C716T nonsynonymous change (T239M, rs 7955866) in FGF23 on the clinical phenotype in a family with autosomal dominant hypophosphatemic rickets
Siena, Italy
Karl Michaëlsson
Sun 19 09:30
OC1.4
Plenary Orals 1
Intake and serum levels of α-tocopherol in relation to fractures in elderly women and men
Mon 20 15:15
OP14
Oral Posters 2: Clinical
Impact of hip fracture on mortality and life expectancy
Madhusmita Misra
Boston, USA
Sun 19 11:30
W1.2
Workshop 1: Fat and bone
Anorexia and bone
Boston, USA
Alireza Moayyeri
London, UK
Mon 20 09:50
OC3.6
Plenary Orals 3
Causal metabolomic pathways to osteoporosis in elderly women
London, UK
Suzanne Morin
Montréal, Canada
Sun 19 09:50
OC1.6
Plenary Orals 1
Femur Geometrical Parameters in the Pathogenesis of Atypical Femur Fractures
Montréal, Canada
Christian Muschitz
Vienna, Austria
Mon 20 19:25
Satellite Symposium - New evidence for osteoporosis therapy - Supported by Amgen in collaboration with GSK
Transitioning osteoporosis therapies: what is the evidence?
Vienna, Austria
Andreas Niemeier
Mon 20 15:05
OP32
Oral Posters 2: Pre-clinical
Hepatic lipase is expressed by osteoblasts and modulates bone remodeling in obesity
Rami Obaid
Edinburgh, UK
Sun 19 21:25
PP230
ECTS New Investigator Seminar and Social Gathering
Depletion of the autophagy adaptor OPTN leads to increased osteoclast formation, fusion and survival as well as increase NF-κB activation in vitro
Edinburgh, UK
Barbara Obermayer-Pietsch
Mon 20 17:30
ES2.3
Educational Symposium 2
Low vitamin D
Claes Ohlson
Gothenburg, Sweden
Sat 18 10:30
CU1.3
Clinical Update 1
Male osteoporosis
Gothenburg, Sweden
Karla Oldknow
Midlothian, UK
Tue 21 09:50
OC6.6
Orals 6 - Mineralisation and energy metabolism
An Emerging Role of PHOSPHO1 in the Regulation of Energy Metabolism 
Midlothian, UK
Cécile Olejnik
Lille, France
Sun 19 21:10
PP38
ECTS New Investigator Seminar and Social Gathering
Bisphosphonate influence on bone quality at molecular level: study of human jaw bone sequesters by Raman microspectroscopy
Lille, France
Isabel Orriss
London, UK
Tue 21 09:00
OC6.1
Orals 6 - Mineralisation and energy metabolism
NPP1 (ecto-nucleotide pyrophosphatase/phosphodiesterase 1) is a key regulator of skeletal and soft tissue mineralisation
London, UK
Klaus Pantel
Hamburg, Germany
Tue 21 11:45
W6.2
Workshop 6: Cancer cells and Bone
Biology and clinical relevance of circulating tumour cells
Hamburg, Germany
Alexandra Papaiouannou
Hamilton, Canada
Sat 18 16:15
Satellite Symposium - Treatment of Severe Osteoporosis: an update - supported by Lilly
Role of Gender and Etiology in the Response to Bone Active Agents in Patients with Osteoporosis
Hamilton, Canada
Julie Pasco
Geelong, Australia
Mon 20 15:20
OP15
Oral Posters 2: Clinical
Fracture risk among men, in relation to osteopenia and osteoporosis defined by areal bone mineral density.
Geelong, Australia
George Peat
Keele, UK
Sun 19 16:40
ES1.1
Educational Symposium 1
Epidemiology
Keele, UK
Adolfo Perez
Barcelona, Spain
Mon 20 11:00
W3.1
Workshop 3: Vertebral fractures
The impact of vertebral fractures on morbidity and mortality
Barcelona, Spain
Mon 20 12:45
MTP9
Meet the Professor Sessions
Failure of osteoporosis treatment - Room 5B
Barcelona, Spain
Ulrika Pettersson-Kymmer
Umeå, Sweden
Sun 19 15:35
OP8
Oral Posters 1: Clinical
Genome-Wide Association Study meta-analysis identifies the SOAT1/AXDND1 locus to be associated with hip and forearm fracture risk
Umeå, Sweden
K Poole
Zug, Switzerland
Mon 20 15:30
OP17
Oral Posters 2: Clinical
Denosumab is associated with progressive improvements in hip cortical mass and thickness
Zug, Switzerland
Sophie Portron
Nantes, France
Sun 19 15:20
OP25
Oral Posters 1: Pre-clinical
Oxygen tension-mediated regulation of chondrogenic differentiation: application to stem cells based osteochondral repair
Nantes, France
Tero Puolakkainen
Turku, Finland
Sun 19 09:00
OC2.1
Plenary Orals 2
Treatment With Soluble Activin Type IIB-Receptor Improves Bone Mass And Strength In A Mouse Model Of Duchenne Muscular Dystrophy
Turku, Finland
Stuart Ralston
Edinburgh, UK
Mon 20 12:45
MTP8
Meet the Professor Sessions
What does bone genetics tell us on bone physiology - Room 5A
Edinburgh, UK
Mon 20 15:25
OP16
Oral Posters 2: Clinical
Long-term effects of symptomatic versus intensive bisphosphonate therapy for Paget's disease of bone: The PRISM-EZ study.
Edinburgh, UK
Francois Rannou
Paris, France
Sun 19 17:30
ES1.3
Educational Symposium 1
Management of osteoarthritis
Paris, France
Professor Martina Rauner
Dresden, Germany
Tue 21 13:00
NIW3
New Investigator Workshop 3
How to get started as a posdoc
Dresden, Germany
Ian Reid
Auckland, New Zealand
Sun 19 15:05
OP2
Oral Posters 1: Clinical
Meta-Analysis of the Effects of Vitamin D Supplements on Bone Mineral Density in Adults
Auckland, New Zealand
Lars Rolighed
Sat 18 14:40
PP286
Allied Health Professionals (AHP) Session continued
Abstract Presentation - Muscle function and quality of life in primary hyperparathyroidism
Bjorn Rosengren
Malmo, Sweden
Mon 20 15:10
OP13
Oral Posters 2: Clinical
Hip Fracture Trends in Denmark 1980-2010 with Age-Period-Cohort-effects
Malmo, Sweden
Christian Roux
Paris, France
Sat 18 14:00
CU2.4
Clinical Update 2
Osteoporosis in ankylosing spondylitis
Paris, France
Sun 19 18:35
Satellite Symposium - Current and Future Strategies for the Management of Osteoporosis: Signaling a Change in the Conversation - Supported by MSD
Optimizing Therapy in Osteoporosis
Paris, France
Davide Ruffoni
Zurich, Switzerland
Sun 19
Awards 2
2010 ECTS POSTDOCTORAL FELLOWSHIP
Zurich, Switzerland
Graham Russell
Oxford, UK
Sat 18 18:30
OPC3
Opening Ceremony: ECTS 50th Anniversary Symposium: 50 years of research in bone and mineral metabolism
50 years of progress in treatment of bone diseases
Oxford, UK
Sun 19 20:00
ECTS New Investigator Seminar and Social Gathering
Plenary Session: Bone Research – The Next 50 Years
Oxford, UK
Georg Schett
Erlangen, Germany
Sat 18 12:30
CU2.1
Clinical Update 2
Osteo-immunology, the basic concepts
Erlangen, Germany
Ansgar Schulz
Ulm, Germany
Mon 20 12:00
W4.3
Workshop 4: Osteoclast activity and haematopoiesis
Osteoclasts and haematopoietic stem cell transplantation in clinical practice
Ulm, Germany
Nicole Scully
Cardiff, UK
Sun 19 15:00
OP21
Oral Posters 1: Pre-clinical
IGF-1 regulates MC-3T3 and human primary osteoblast to osteocyte differentiation in 3D culture
Cardiff, UK
Ego Seeman
Melbourne, Australia
Sun 19 19:15
Satellite Symposium - Current and Future Strategies for the Management of Osteoporosis: Signaling a Change in the Conversation - Supported by MSD
Odanacatib: A Novel Approach to the Treatment of Osteoporosis
Melbourne, Australia
Jochen Seufert
Tue 21 08:30
S4.2
Symposium 4: Energy metabolism and bone
Sweet bones - the effect of diabetes on bone
Majken Siersbaek
Odense C, Denmark
Sun 19 21:20
PP175
ECTS New Investigator Seminar and Social Gathering
Identification of a small molecule kinase inhibitor that enhances osteoblast differentiation of human skeletal (mesenchymal) stem cells through regulation of TGFβ signaling
Odense C, Denmark
Saba Silva
Lisbon, Portugal
Tue 21 13:00
MTP15
Meet the Professor Sessions
State-of the-Art techniques in Bone research - Room 5C
Lisbon, Portugal
Kathrin Sinningen
Dresden, Germany
Sun 19 15:30
OP27
Oral Posters 1: Pre-clinical
Milk fat globule-epidermal growth factor 8 (MFG-E8) is a critical determinant of bone mass and alters the course of inflammation in arthritis
Dresden, Germany
Antonia Sophocleous
Edinburgh, UK
Mon 20 09:00
OC3.1
Plenary Orals 3
Heavy cannabis use negatively impacts on bone density - a population based prospective study
Edinburgh, UK
Katherine Staines
Edinburgh, Scotland
Sun 19 21:00
PP27
ECTS New Investigator Seminar and Social Gathering
Sclerostin/MEPE axis in OA: lessons from long bone development
Edinburgh, Scotland
Laufey Steingrimsdottir
Reykjavik, Iceland
Sun 19 09:10
OC1.2
Plenary Orals 1
Hip fractures and bone mineral density of the elderly - importance of serum 25-hydroxy vitamin D
Reykjavik, Iceland
Jan Stepán
Sat 18 15:50
Satellite Symposium - Treatment of Severe Osteoporosis: an update - supported by Lilly
Effects of Bone Active Agents on Cortical Bone
Andrea Superti-Furga
Lausanne, Switzerland
Mon 20 08:30
S3.2
Symposium 3: Extreme bone phenotypes
Insights from research in bone genetics: what do genetic skeletal disorders tell us on bone physiology?
Lausanne, Switzerland
Hiroshi Takayanagi
Toyko, Japan
Tue 21 14:00
S5.1
Symposium 5: Uncoupling of resorption and formation
Novel antiresorptives - uncoupling or not?
Toyko, Japan
Viviana Tavares
Lisbon, Portugal
Mon 20 12:00
W3.3
Workshop 3: Vertebral fractures
Treatment of vertebral fractures
Lisbon, Portugal
Mon 20 12:45
MTP10
Meet the Professor Sessions
New osteoporosis treatment modalities - Room 5C
Lisbon, Portugal
Sylvia Thiele
Dresden, Germany
Mon 20 09:30
OC4.4
Plenary Orals 4
Glucocorticoid exposure reduces expression of sclerostin in bone marrow stromal cells
Dresden, Germany
Cyril Thouverey
Geneva, Switzerland
Mon 20 09:10
OC4.2
Plenary Orals 4
The p38alpha MAPK pathway in osteoblasts contributes to ovariectomy-induced bone loss by upregulating interleukin-6 expression
Geneva, Switzerland
André Uitterlinden
Rotterdam, The Netherlands
Sun 19
NIW1
New Investigator Workshop 1
Genomics and proteomics as emerging technologies in bone research
Rotterdam, The Netherlands
Karmele Valencia
Pamplona, Spain
Sun 19 15:40
OP29
Oral Posters 1: Pre-clinical
miR-192 Impairs Invasion and Tumor-Induced Osteolysis by Repressing CCL2 in Bone Metastatic Colonization
Pamplona, Spain
Peter Vestergaard
Aalborg, Denmark
Sun 19 09:40
OC1.5
Plenary Orals 1
Heart failure in patients treated with bisphosphonates
Aalborg, Denmark
David Vicente
Oulu, Finland
Tue 21 09:20
OC6.3
Orals 6 - Mineralisation and energy metabolism
Collagen XV as a bone matrix organizer
Oulu, Finland
Andrea Vortkamp
Essen, Germany